Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

Dana-Farber Cancer Institute

Status: Enrolling

Conditions: Peripheral Primitive Neuroectodermal Tumor of Bone; High-grade Osteosarcoma; Ewing Sarcoma of Bone; Peripheral Primitive Neuroectodermal Tumor of Soft Tissue; Ewing Sarcoma; Ewing Sarcoma of Soft Tissue; Peripheral Primitive Neuroectodermal Tumor

Treatments: Other: FoundationOne Liquid CDx

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT06068075

18-138

Details and patient eligibility

About

This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.

Full description

The purpose of this study is to evaluate whether ctDNA in the blood can provide information about the chances of Ewing sarcoma or osteosarcoma coming back after treatment. This research study is evaluating a new advanced laboratory test to detect small pieces of tumor genes in the peripheral blood known as circulating tumor DNA (ctDNA).

Part A : During this part of the research study (Part A) participants will be asked to provide blood samples at pre-defined times. These blood samples may help find specific genetic alterations commonly seen in Ewing sarcoma or osteosarcoma that may allow investigators to learn more about the uses of ctDNA. The results of the ctDNA analysis will not be returned to participants.

Approximately 90 patients will take part in this study across multiple centers.

Part B: This research study is evaluating new advanced laboratory tests to detect small pieces of tumor genes in the peripheral blood known as circulating tumor DNA (ctDNA). Part B of the research study, which focuses on ctDNA tests that can be returned to providers and patients with Ewing sarcoma. This part of the study will allow comparison of commercial ctDNA testing from Foundation Medicine to our research testing. It is expected that about 60 people with Ewing sarcoma will take part in Part B of this research study.

The sponsor of this protocol is Dana-Farber Cancer Institute and is providing funding for the study. Additional funding for this study is provided by the Conquer Cancer Foundation of the American Society of Clinical Oncology, Alex's Lemonade Stand Foundation, Boston Children's Hospital Office of Faculty Development, the Friends of Dana-Farber Cancer Institute, The Harvard Catalyst Program, and the Spada Pediatric Sarcoma Foundation

Enrollment: 340 estimated patients

Sex: All

Ages: 12 months to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• For Part A, subjects must meet all of the following eligibility criteria.

• Age: ≥ 12 months of age at time of study enrollment to 50 years of age

• Diagnosis: Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed, localized or regionally disseminated Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) of bone or soft tissue or; Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed, non-pelvic, localized or regionally disseminated high-grade osteosarcoma. NOTE: Staging will be assessed according to standard of care at the treating center.

• Prior Therapy:

  • Patients should have only previously had a biopsy, and not had prior attempt at tumor resection.
  • Not yet started chemotherapy or radiation therapy OR patient has started chemotherapy or radiation therapy, but an appropriate pre-treatment baseline sample was collected and processed for ctDNA under a local banking study in DFCI Pediatrics and is available to use for this study.

• Planned to receive chemotherapy as follows:

  -- VDC/IE as per COG protocols AEWS0031, AEWS1031 or AEWS1221 (for patients with Ewing sarcoma or PNET); or MAP as per COG protocol AOST0331 (for patients with osteosarcoma).

• For Part B subjects must meet all of the following eligibility criteria.

• Age: ≥ 12 months of age at time of study enrollment

• Diagnosis: Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) of bone or soft tissue

• Prior Therapy:

  • Patients should have had only frontline therapy as per institutional standard, and maintenance therapy if given (no relapse therapy).
  • If frontline systemic therapy already completed (not including maintenance or metastatic site radiation), therapy completed within 6 months of enrollment to Part B.
  • Subjects must have a willing physician provider supporting their participation in Part B.

• For Part B, providers are eligible to receive the provider survey if they are listed as the primary provider for the patient at the study site.

Exclusion criteria

• For Part A, subjects must not meet any of the following exclusion criteria.
• Patients with distant metastatic disease.
• Patients with known Ewing-like sarcoma (e.g., BCOR-CCNB3 or CIC-DUX4 translocated small round cell sarcomas) are not eligible.
• Patients who are enrolled with an initial diagnosis of Ewing sarcoma and subsequently found to have Ewing-like sarcoma will be replaced. Samples obtained prior to removal from study will be analyzed and reported descriptively. Patients with Ewing-like tumors may continue to provide samples and clinical data until they meet off-study criteria per protocol.
• Patients weighing < 5 kg at time of diagnosis
• Patients with a second malignant neoplasm
• Patients without detectable tumor at the time of study enrollment (ie, complete tumor resection prior to study enrollment)
• Patients already receiving tumor-directed therapy at the time of study enrollment except when a pre-treatment baseline sample has already been obtained under a local banking study in DFCI Pediatrics that would be eligible for analysis under this study.
• Patients with osteosarcoma with a pelvic primary tumor site Pregnancy
• For Part B, subjects must not meet any of the following exclusion criteria.
• Patients with known Ewing-like sarcoma (e.g., BCOR-CCNB3 or CIC-DUX4 translocated small round cell sarcomas) are not eligible.
• Samples obtained prior to removal from study will be analyzed and reported descriptively. Patients with Ewing-like tumors may continue to provide samples and clinical data until they meet off-study criteria per protocol
• Patients weighing < 5 kg at time of enrollment
• Patients diagnosed with relapsed disease and/or having started therapy directed at disease relapse
• Pregnancy
• Resides outside of the United States
• For Part B, providers at non-study centers will not be eligible to receive the provider survey.

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

340 participants in 2 patient groups

REG EWING or OSTEO: ctDNA EVALUATION

No Intervention group

Description:

This study involves collection of blood samples at pre-specified time points as well as collection of information about this disease. For each timepoint, submit two tubes of blood (17 mL total or a little more than 3 teaspoons) per standard ctDNA workflow

EWING ctDNA RETURN OF RESULTS

Experimental group

Description:

This study involves collection of blood samples at pre-specified time points as well as collection of information about this disease. For each timepoint, submit two tubes of blood (17 mL total or a little more than 3 teaspoons) to a commercial testing laboratory called Foundation Medicine and one tube of blood (10 mL or 2 teaspoons) to standard ctDNA workflow

Treatment:

Other: FoundationOne Liquid CDx